Roman Hájek is Professor of Oncology, Head of the Department of Haematooncology in the University Hospital Ostrava and Vice-Rector for Strategy and Development at the University of Ostrava, Czech Republic. After qualifying in medicine in 1988 from J.E. Purkyne /Masaryk/ University Faculty of Medicine Brno, Dr Hajek received a PhD in haematology in 1995 and completed degrees in Internal Medicine in 1996 and in Medical Oncology in 1998.
Dr Hájek is chairman and a founding member of the Czech Myeloma Group. Currently there are more than 6000 MM and more than 2000 MGUS patients’ clinical data in RMG (Registry of Monoclonal Gammopathy) what enables to perform various “real life” statistical analyses of risk groups and prognostic markers. He also established central biobank for the Czech Republic.
Dr Hájek serves on the scientific advisory board of the International Myeloma Foundation (IMF), and is a member of the International Myeloma Society (IMS), International Myeloma Working Group (IMWF), European Myeloma Society, European Myeloma Network, and American Society of Hematology (ASH).
Dr Hájek has published over 430 scientific articles (h-index: 38; cumulative IF of papers > 660) and book chapters and is an editor of the European Journal of Hematology. His research interests include MM, bone marrow transplantation, and immunotherapy. Dr Hajek is also interested in finding new prognostic and predictive markers for high risk MM, as well as for the progression of monopathic gammopathies of undetermined significance (MGUS) to MM.